References
1. Sandbank S, Molho-Pessach V, Farkas A, Barzilai A, Greenberger S:Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review . Acta dermato-venereologica 2019,99 (11):990-996.
2. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM: Sirolimus for the treatment of complicated vascular anomalies in children . Pediatric blood & cancer 2011, 57 (6):1018-1024.
3. Adams DM, Trenor CC, 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C et al :Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies . Pediatrics 2016, 137 (2):e20153257.
4. Hammer J, Seront E, Duez S, Dupont S, Van Damme A, Schmitz S, Hoyoux C, Chopinet C, Clapuyt P, Hammer F et al : Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study . Orphanet journal of rare diseases 2018, 13 (1):191.
5. Ricci KW, Hammill AM, Mobberley-Schuman P, Nelson SC, Blatt J, Bender JLG, McCuaig CC, Synakiewicz A, Frieden IJ, Adams DM: Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease . Pediatric blood & cancer 2019,66 (5):e27614.
6. Wong XL, Phan K, Rodriguez Bandera AI, Sebaratnam DF:Sirolimus in blue rubber bleb naevus syndrome: A systematic review . Journal of paediatrics and child health 2019,55 (2):152-155.
7. Wang Z, Yao W, Sun H, Dong K, Ma Y, Chen L, Zheng S, Li K:Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up . The Journal of dermatology 2019,46 (11):956-961.
8. Limaye N, Kangas J, Mendola A, Godfraind C, Schlogel MJ, Helaers R, Eklund L, Boon LM, Vikkula M: Somatic Activating PIK3CA Mutations Cause Venous Malformation . Am J Hum Genet 2015,97 (6):914-921.
9. Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, Rialon KL, Guevara CJ, Alomari AI, Greene AK et al : Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA . The Journal of pediatrics 2015,166 (4):1048-1054 e1041-1045.
10. Blesinger H, Kaulfuss S, Aung T, Schwoch S, Prantl L, Rossler J, Wilting J, Becker J: PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations . PLoS One 2018, 13 (7):e0200343.
11. Venot Q, Canaud G: [PIK3CA-related overgrowth syndrome (PROS)] . Nephrologie & therapeutique 2017, 13 Suppl 1 :S155-S156.
12. Russell TB, Rinker EK, Dillingham CS, Givner LB, McLean TW:Pneumocystis Jirovecii Pneumonia During Sirolimus Therapy for Kaposiform Hemangioendothelioma . Pediatrics 2018,141 (Suppl 5):S421-S424.
13. Ying H, Qiao C, Yang X, Lin X: A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas . Pediatrics 2018, 141 (Suppl 5):S425-S429.
14. Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, Sapp JC, Andrews K, Bardou M, Chen KY et al : Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum . Genetics in medicine : official journal of the American College of Medical Genetics 2019, 21 (5):1189-1198.
15. Sindhi R: Sirolimus in pediatric transplant recipients .Transplantation proceedings 2003, 35 (3 Suppl):113S-114S.
16. Roque EJ, Rios MG, Vignolo AP, Pinochet VC, Schultz M, Humeres AR, Delucchi A, Rius AM, Hepp KJ: [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation] .Revista medica de Chile 2008, 136 (5):631-636.
17. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT: Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial . Blood 2016,127 (1):17-28.
18. Lackner H, Karastaneva A, Schwinger W, Benesch M, Sovinz P, Seidel M, Sperl D, Lanz S, Haxhija E, Reiterer F et al :Sirolimus for the treatment of children with various complicated vascular anomalies . European journal of pediatrics 2015,174 (12):1579-1584.
19. Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, Blanc E, Johnson SC, Hoguin C, Boccara O et al : Targeted therapy in patients with PIK3CA-related overgrowth syndrome .Nature 2018, 558 (7711):540-546.